fananserin has been researched along with Dementia Praecox in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristow, LJ; Hutson, PH; Rowley, M | 1 |
| Fabre, LF; Meltzer, HY; Papillon-Downey, C; Rivière, ME; Tamminga, CA; Truffinet, P | 1 |
| Cutler, NR; Davidson, J; Hourani, J; Jhee, SS; Kirkesseli, S; Paccaly-Moulin, A; Sémiond, D; Sramek, JJ | 1 |
1 review(s) available for fananserin and Dementia Praecox
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
2 trial(s) available for fananserin and Dementia Praecox
| Article | Year |
|---|---|
Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.
Topics: Adolescent; Adult; Cyclic S-Oxides; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Naphthalenes; Patient Dropouts; Placebo Effect; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Treatment Outcome | 1999 |
A bridging study of fananserin in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Cyclic S-Oxides; Female; Humans; Male; Middle Aged; Naphthalenes; Schizophrenia | 1998 |